国际肿瘤学杂志››2021,Vol. 48››Issue (4): 250-253.doi:10.3760/cma.j.cn371439-20200903-00050
收稿日期:
2020-09-03修回日期:
2020-12-10出版日期:
2021-04-08发布日期:
2021-06-18通讯作者:
彭效祥 E-mail:pxx74@sina.com基金资助:
Li Qianqian, Zhu Xiaodi, Zhao Ronglan, Peng Xiaoxiang()
Received:
2020-09-03Revised:
2020-12-10Online:
2021-04-08Published:
2021-06-18Contact:
Peng Xiaoxiang E-mail:pxx74@sina.comSupported by:
摘要:
P2X7受体是以三磷酸腺苷(ATP)为配体的离子通道型受体,在多种免疫细胞和组织中广泛表达,其激活后可参与多种生理和病理过程。P2X7受体在结肠癌中异常表达,并在结肠癌的进展中发挥抑癌和促癌双重作用。P2X7受体被细胞外的ATP激活后,可通过多种机制有效抑制结肠癌细胞的增殖,并诱导细胞凋亡。另外,P2X7受体还能促进结肠癌的生长、侵袭和转移。了解P2X7受体的激活及其效应机制对于结肠癌的治疗具有重要意义。
李倩倩, 朱晓娣, 赵荣兰, 彭效祥. P2X7受体在结肠癌进展中的作用[J]. 国际肿瘤学杂志, 2021, 48(4): 250-253.
Li Qianqian, Zhu Xiaodi, Zhao Ronglan, Peng Xiaoxiang. Role of P2X7 receptor in colon cancer progression[J]. Journal of International Oncology, 2021, 48(4): 250-253.
[1] | Lv Y, Yang X, Wang L. Effect of lncRNA THOR on proliferation and migration of colon cancer cells[J]. Oncol Lett, 2019, 18(3):2518-2522. DOI: 10.3892/ol.2019.10585. |
[2] | Di Virgilio F, Pelegrín P. Editorial overview: purinergic P2X receptors in innate immunity and inflammation[J]. Curr Opin Pharmacol, 2019, 47:141-144. DOI: 10.1016/j.coph.2019.05.003. doi:10.1016/j.coph.2019.05.003 |
[3] | Zhang WJ, Hu CG, Zhu ZM, et al. Effect of P2X7 receptor on tumorigenesis and its pharmacological properties[J]. Biomed Pharmacother, 2020, 125:109844. DOI: 10.1016/j.biopha.2020.109844. doi:10.1016/j.biopha.2020.109844 |
[4] | Roger S, Jelassi B, Couillin I, et al. Understanding the roles of the P2X7 receptor in solid tumour progression and therapeutic perspectives[J]. Biochim Biophys Acta, 2015, 1848(10 Pt B):2584-2602. DOI: 10.1016/j.bbamem.2014.10.029. doi:10.1016/j.bbamem.2014.10.029 |
[5] | Cao F, Hu LQ, Yao SR, et al. P2X7 receptor: a potential therapeutic target for autoimmune diseases[J]. Autoimmun Rev, 2019, 18(8):767-777. DOI: 10.1016/j.autrev.2019.06.009. doi:10.1016/j.autrev.2019.06.009 |
[6] | Ribeiro DE, Roncalho AL, Glaser T, et al. P2X7 receptor signaling in stress and depression[J]. Int J Mol Sci, 2019, 20(11): 2778. DOI: 10.3390/ijms20112778. doi:10.3390/ijms20112778 |
[7] | Di Virgilio F, Adinolfi E. Extracellular purines, purinergic receptors and tumor growth[J]. Oncogene, 2017, 36(3):293-303. DOI: 10.1038/onc.2016.206. doi:10.1038/onc.2016.206pmid:27321181 |
[8] | Furini F, Giuliani AL, Parlati ME, et al. P2X7 receptor expression in patients with serositis related to systemic lupus erythematosus[J]. Front Pharmacol, 2019, 10:435. DOI: 10.3389/fphar.2019.00435. doi:10.3389/fphar.2019.00435 |
[9] | Amoroso F, Salaro E, Falzoni S, et al. P2X7 targeting inhibits growth of human mesothelioma[J]. Oncotarget, 2016, 7(31):49664-49676. DOI: 10.18632/oncotarget.10430. doi:10.18632/oncotarget.v7i31 |
[10] | Choi JH, Ji YG, Ko JJ, et al. Activating P2X7 receptors increases proliferation of human pancreatic cancer cells via ERK1/2 and JNK[J]. Pancreas, 2018, 47(5):643-651. DOI: 10.1097/MPA.0000000000001055. doi:10.1097/MPA.0000000000001055pmid:29683976 |
[11] | Xia J, Yu X, Tang L, et al. P2X7 receptor stimulates breast cancer cell invasion and migration via the AKT pathway[J]. Oncol Rep, 2015, 34(1):103-110. DOI: 10.3892/or.2015.3979. doi:10.3892/or.2015.3979 |
[12] | Hofman P, Cherfils-Vicini J, Bazin M, et al. Genetic and pharmacological inactivation of the purinergic P2RX7 receptor dampens inflammation but increases tumor incidence in a mouse model of colitis-associated cancer[J]. Cancer Res, 2015, 75(5):835-845. DOI: 10.1158/0008-5472.CAN-14-1778. doi:10.1158/0008-5472.CAN-14-1778 |
[13] | 陆嫄, 顾沐恩, 丁邦友, 等. 艾灸对结肠炎相关性结肠癌大鼠P2X7受体、Wnt/β-catenin信号通路影响的研究[J]. 上海针灸杂志, 2020, 39(6):758-765. DOI: 10.13460/j.issn.1005-0957.2020.13.1042. |
[14] | Wang J, Cheng M, Law IKM, et al. Cathelicidin suppresses colon cancer metastasis via a P2RX7-dependent mechanism[J]. Mol Ther Oncolytics, 2019, 12:195-203. DOI: 10.1016/j.omto.2019.01.004. doi:10.1016/j.omto.2019.01.004 |
[15] | Adinolfi E, Capece M, Franceschini A, et al. Accelerated tumor progression in mice lacking the ATP receptor P2X7[J]. Cancer Res, 2015, 75(4):635-644. DOI: 10.1158/0008-5472.CAN-14-1259. doi:10.1158/0008-5472.CAN-14-1259 |
[16] | Di Virgilio F, Sarti AC, Falzoni S, et al. Extracellular ATP and P2 purinergic signalling in the tumour microenvironment[J]. Nat Rev Cancer, 2018, 18(10):601-618. DOI: 10.1038/s41568-018-0037-0. doi:10.1038/s41568-018-0037-0 |
[17] | He Y, Taylor N, Fourgeaud L, et al. The role of microglial P2X7: modulation of cell death and cytokine release[J]. J Neuroinflammation, 2017, 14(1):135. DOI: 10.1186/s12974-017-0904-8. doi:10.1186/s12974-017-0904-8 |
[18] | Bian S, Sun X, Bai A, et al. P2X7 integrates PI3K/AKT and AMPK-PRAS40-mTOR signaling pathways to mediate tumor cell death[J]. PLoS One, 2013, 8(4): e60184. DOI: 10.1186/s12974-017-0904-8. doi:10.1371/journal.pone.0060184 |
[19] | Coutinho-Silva R, Stahl L, Cheung KK, et al. P2X and P2Y purinergic receptors on human intestinal epithelial carcinoma cells: effects of extracellular nucleotides on apoptosis and cell proliferation[J]. Am J Physiol Gastrointest Liver Physiol, 2005, 288(5): G1024-G1035. DOI: 10.1152/ajpgi.00211.2004. doi:10.1152/ajpgi.00211.2004 |
[20] | Souza CO, Santoro GF, Figliuolo VR, et al. Extracellular ATP induces cell death in human intestinal epithelial cells[J]. Biochim Biophys Acta, 2012, 1820(12):1867-1878. DOI: 10.1016/j.bbagen.2012.08.013. |
[21] | de Andrade Mello P, Bian S, Savio LEB, et al. Hyperthermia and associated changes in membrane fluidity potentiate P2X7 activation to promote tumor cell death[J]. Oncotarget, 2017, 8(40):67254-67268. DOI: 10.18632/oncotarget.18595. doi:10.18632/oncotarget.v8i40 |
[22] | Adinolfi E, Raffaghello L, Giuliani AL, et al. Expression of P2X7 receptor increases in vivo tumor growth[J]. Cancer Res, 2012, 72(12):2957-2969. DOI: 10.1158/0008-5472.CAN-11-1947. doi:10.1158/0008-5472.CAN-11-1947 |
[23] | Janakiram NB, Mohammed A, Bryant T, et al. Adoptive transfer of regulatory T cells promotes intestinal tumorigenesis and is associated with decreased NK cells and IL-22 binding protein[J]. Mol Carcinog, 2015, 54(10):986-998. DOI: 10.1002/mc.22168. doi:10.1002/mc.22168 |
[24] | 方伟岗, 田新霞. 肿瘤微环境中一种新型促侵袭因子的发现——细胞外ATP功能及机制的研究进展[J]. 北京大学学报(医学版), 2017, 49(2):188-195. DOI: 10.3969/j.issn.1671-167X.2017.02.002. |
[25] | Zhang Y, Ding J, Wang L. The role of P2X7 receptor in prognosis and metastasis of colorectal cancer[J]. Adv Med Sci, 2019, 64(2):388-394. DOI: 10.1016/j.advms.2019.05.002. doi:10.1016/j.advms.2019.05.002 |
[26] | Qian F, Xiao J, Hu B, et al. High expression of P2X7R is an in-dependent postoperative indicator of poor prognosis in colorectal cancer[J]. Hum Pathol, 2017, 64:61-68. DOI: 10.1016/j.humpath.2017.03.019. doi:10.1016/j.humpath.2017.03.019 |
[27] | Kaltschmidt B, Greiner JFW, Kadhim HM, et al. Subunit-specific role of NF-κB in cancer[J]. Biomedicines, 2018, 6(2):44. DOI: 10.3390/biomedicines6020044. doi:10.3390/biomedicines6020044 |
[28] | Xia Y, Shen S, Verma IM. NF-κB, an active player in human can-cers[J]. Cancer Immunol Res, 2014, 2(9):823-830. DOI: 10.1158/2326-6066.CIR-14-0112. doi:10.1158/2326-6066.CIR-14-0112 |
[1] | 许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363. |
[2] | 冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英.HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531. |
[3] | 黄辉, 丁江华.靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573. |
[4] | 王文德, 曾德.乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356. |
[5] | 张丽, 向卓, 王强, 毕经旺.CAR-T免疫治疗相关的细胞因子释放综合征研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 377-381. |
[6] | 丁浩, 应劲涛, 付茂勇.CAR-T在食管鳞状细胞癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 231-235. |
[7] | 朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏.HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240. |
[8] | 李佳璇, 封颖璐.糖皮质激素受体在肝癌细胞生长中的作用机制[J]. 国际肿瘤学杂志, 2023, 50(4): 241-243. |
[9] | 宁婷婷, 胡钦勇, 李倩, 杨鹏程.奥希替尼与埃克替尼一线治疗EGFR阳性转移性NSCLC临床疗效观察[J]. 国际肿瘤学杂志, 2023, 50(2): 65-70. |
[10] | 张碧霞, 丁江华.EGFR突变型非小细胞肺癌EGFR-TKI获得性耐药后免疫治疗现状[J]. 国际肿瘤学杂志, 2023, 50(2): 97-101. |
[11] | 于晓鹏, 冯青青, 赵文飞, 赵文文, 魏红梅.靶向治疗联合免疫检查点抑制剂在HER2阳性进展期胃癌中的应用[J]. 国际肿瘤学杂志, 2023, 50(10): 631-635. |
[12] | 许婷婷, 胡超苏, 李宝生.抗EGFR单抗治疗局部晚期头颈部鳞状细胞癌临床共识(2023年版)[J]. 国际肿瘤学杂志, 2023, 50(1): 1-11. |
[13] | 徐航程, 吴云, 王佳玉.HER2低表达乳腺癌研究进展[J]. 国际肿瘤学杂志, 2022, 49(9): 513-516. |
[14] | 褚雪镭, 毛昀, 薛鹏, 李林潞, 陈美池, 袁淳晟, 秦晓艳, 朱世杰.化疗剂量强度对晚期结肠癌患者近期疗效的影响:基于真实世界数据研究[J]. 国际肿瘤学杂志, 2022, 49(7): 408-415. |
[15] | 徐忠玲, 王珏, 郑广, 何欣.卡瑞利珠单抗联合阿帕替尼治疗十二指肠癌1例[J]. 国际肿瘤学杂志, 2022, 49(7): 447-448. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||